Drug intelligence / Profile preview

AT-401

Development stage: Preclinical
Lead developer: A28 Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AT-401 is a preclinical-stage antibody-drug conjugate (ADC) being developed by A28 Therapeutics. It is engineered to dual-target CD20 and HER2 (Human Epidermal Growth Factor Receptor 2), facilitating the selective delivery of a cytotoxic payload to tumor cells expressing these antigens. This dual-targeting approach is intended to improve therapeutic precision and potentially overcome resistance mechanisms or address tumor heterogeneity in various malignancies. As of early 2026, the candidate remains in the preclinical phase of development.

Other names: AT-401AT401AT 401

Targets

CD20 (B-lymphocyte antigen CD20)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on AT-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-401.

Explore the full profile